新型冠状病毒序列变异时空分析系统的设计与实现

新型冠状病毒肺炎目前已进入全球大流行状态,多个国家出现疫情爆发。美国疾病管制局期刊《新兴传染病》发表的关于新型冠状病毒的最新研究结论显示,新型冠状病毒基本传染数R0的中位数高达5.7,这意味着在未来较长时间内新型冠状病毒可能会在人群中持续传播并发生变异。在这一背景下,如何监视病毒的变异,对于冠状病毒的研究和药物研发具有重要意义。本文基于来自GISAID的病毒基因组序列数据,设计和实现了新型冠状病毒变异时空分析系统。该系统可对来自不同国家和地区的新型冠状病毒序列数进行统计,对病毒序列在不同时间、不同空间内的变异情况进行分析和可视化,同时还支持不同序列之间的差异比对。该系统可为新型冠状病毒肺炎的研究和政府的疾病控制机构的决策提供支持。     

新型冠状病毒基因组结构与蛋白功能

2019年12月以来,武汉市暴发新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)疫情并迅速蔓延全国,2020年1月30日被世界卫生组织(World Health Organization,WHO)列为“国际关注的突发公共卫生事件”(public health emergency of international concern,PHEIC)。核酸序列分析证明COVID-19由新型冠状病毒(2019 novel coronavirus,2019-nCoV)引起。2019-nCoV为正链单链RNA病毒,基因组长约30 kb,两端为非编码区,中间为非结构蛋白编码区和结构蛋白编码区。非结构蛋白编码区主要包括开放读码框架(open reading frame,ORF)1a和ORF1b基因,编码16个非结构蛋白(non-structural proteins,NSP),即NSP1～16。结构蛋白编码区主要编码刺突(spike,S)蛋白、包膜(envelope,E)蛋白、膜(membrane,M)蛋白和核衣壳(nucleocapsid,N)蛋白。深入了解2019-nCoV基因组的结构和蛋白功能,将为2019-nCoV相关的病毒溯源、复制增殖、致病免疫、药物与疫苗研发以及当前疫情的防控提供有力的支撑。     

安徽省境外输入新冠病毒Delta变异株的首次发现与鉴定

为鉴定此次安徽省境外输入新型冠状病毒的分子特征,本研究对两例病例进行了高通量测序和基因组序列分析。高通量测序获得两株病毒的基因组全长分别为29 858nt和29 858nt,利用NextStrain和2019新型冠状病毒信息库（https：//ngdc.cncb.ac.cn/ncov/）在线分析对两例毒株全基因组核苷酸和氨基酸变异位点进行分析。将全基因组序列上传到（https：//pangolin.cog-uk.io）和（https：//clades.nextstrain.org/）网站,通过在线网站分析结果显示,两株病毒均为B.1.617.2变异株（Delta）,NextStrain进化分析为21A。两株毒株分别发现了49和48个核苷酸突变位点,氨基酸的变异位点分别有35和34个,其中存在相同的7个同义突变。两株病毒主要在ORF7a基因上C27527T(P45L)的突变不同。这是安徽省首次发现境外输入的B.1.617.2变异株（Delta株）此变异株存在引发本地的流行和爆发的风险,需要严密持续的对境外输入病例进行流行病学调查和病毒基因分子特征分析。     

2019新型冠状病毒S蛋白可能存在Furin蛋白酶切位点

2019年12月,中国武汉报道了2019新型冠状病毒(2019 novel Coronavirus,2019-nCoV)引起的肺炎。基于基因组信息,我们前期研究结果显示2019-nCoV与SARS冠状病毒虽然同属于Beta冠状病毒B亚群(BB冠状病毒),但两种病毒差异较大,这一结果与两者临床症状差异一致。前期研究还发现了BB冠状病毒存在大量的可变翻译,并从分子水平揭示了BB冠状病毒变异快、多样性高的特点。本研究在国际上首次报道Beta冠状病毒S蛋白上的一个重要突变,这个突变使2019-nCoV具有了一个可供Furin蛋白酶切的位点,是大部分Beta冠状病毒(特别是SARS和SARS样(SARS-like)冠状病毒)所不具有的。我们的一个结论是这个突变有可能增强了2019-nCoV侵染细胞的效率,进而使其传播力显著大于SARS冠状病毒。由于这个突变,2019-nCoV的感染机制也会不同于SARS等大部分Beta冠状病毒,而与鼠肝炎冠状病毒、HIV、埃博拉病毒和一些禽流感病毒的感染机制更相似。我们意外发现一些禽流感病毒也可以通过突变获得Furin蛋白酶切位点,这说明自然突变可以引入Furin酶切位点。除此之外,在2019-nCoV的S蛋白中插入的"CGGCGG"序列编码两个精氨酸,然而"CGG"对于宿主(人)来说是蛋白质翻译的稀有密码子。我们的另一个结论是引入Furin蛋白酶切位点的插入突变中包含的"CGGCGG"是传播到人之前形成的;2019-nCoV的中间宿主应该是密码子"CGG"相对使用频率更高的哺乳动物。使用我们提供的密码子"CGG"相对频率表结合2019-nCoV检测阳性的动物样品信息可以准确地确定2019-nCoV的中间宿主。对这个重要突变的后续研究将为揭示2019-nCoV传播力强的原因,以及为药物、抗体和疫苗的开发等工作奠定基础。     

丽水市早期新冠肺炎无症状感染者SARS-CoV-2全基因组序列分析

对1例新型冠状病毒肺炎疫情流行早期的无症状感染者临床标本进行SARS-CoV-2实验室鉴定和全基因组测定,在分子水平了解新型病毒的基因特点和变异情况,追溯病毒潜在来源.实时荧光定量PCR扩增丽水市庆元县首例确诊患者密切接触者的痰液标本SARS-CoV-2核酸,阳性RNA逆转录为cDNA构建文库后进行基于NGS的宏基因组深度测序,生物学软件分析处理数据.该密接无任何症状及体征,痰液标本SARS-CoV-2核酸阳性.测序数据包含有足够的病毒序列,组装成功后hCoV-19/Lishui/LS556/2020长29 887bp,G+C含量37.99％,在ORF1ab和N区域发现4个SNP,对应1个错义突变和3个同义突变.LS556与SARS-CoV-2参考序列核苷酸/氨基酸同源性在99.2％/97.4％以上,不同序列之间存在4～17个核苷酸差异,与蝙蝠病毒RaTG13核苷酸差异仅3.7％,存在1141个SNP,与穿山甲病毒Guangdong/1相似性90.9％.LS556属于β冠状病毒Lineage B谱系,与LS003和ZJU-06共享完全相同的病毒,与蝙蝠/穿山甲冠状病毒进化上最相关.结合流行病学、核酸诊断、病毒溯源判定其为无症状感染者.LS556组成和结构符合SARS-CoV-2典型的基因特征,为高覆盖率序列,在流行早期与其他SARS-CoV-2基因组具有高度的同一性,突变率保持在较低水平,多数导致氨基酸位点保守置换.     

2019新型冠状病毒基因组的生物信息学分析

2019年12月,中国武汉报道了冠状病毒引起的肺炎,其临床症状与2003年爆发的严重急性呼吸综合征(Severe Acute Respiratory Syndrome, SARS)不同,因此推断该病毒可能是冠状病毒的一个新变种。不同于简单使用全基因组序列的其它研究,我们于2018年在国际上首次提出分子功能与进化分析相结合的研究思想,并应用于Beta冠状病毒B亚群(BB冠状病毒)基因组的研究。在这一思想指导下,本研究使用BB冠状病毒基因组中的一个互补回文序列(命名为Nankai complemented palindrome)与其所在的编码区(命名为Nankai CDS)对新发布的2019新型冠状病毒基因组(GenBank:MN908947)进行分析以期准确溯源,并对BB冠状病毒的跨物种传播和宿主适应性进行初步研究。溯源分析的结果支持2019新型冠状病毒源自蝙蝠,但与SARS冠状病毒差异巨大,这一结果与两者临床症状差异一致。本研究的最重要发现是BB冠状病毒存在大量的可变翻译,从分子水平揭示了BB冠状病毒变异快、多样性高的特点。从BB冠状病毒可变翻译中获取的信息可应用于(但不限于)其快速检测、基因分型、疫苗开发以及药物设计。另外,我们推断BB冠状病毒可能通过可变翻译以适应不同宿主。基于大量基因组数据的实证分析,本研究在国际上首次从分子水平尝试解释了BB冠状病毒变异快、宿主多且具有较强的宿主适应性的原因。     

SARS病原体特征与临床实验室诊断

SARS的全球性流行带来了严重的公共卫生问题和社会经济问题。目前,在SARS病原体鉴定、基因组结构和序列变异、SARS流行特征和实验室诊断等方面获得了很大的进展。现已证实SARS的病原体为SARS冠状病毒。SARS冠状病毒是一种与原来已知冠状病毒在某些方面类似、但又独具特征的新型冠状病毒,该病毒的起源可能源于野生动物。多个SARS冠状病毒的全基因组核酸序列测定现已完成,在SARS冠状病毒的实验室诊断方面,现已有了免疫学方法检查抗体和分子生物学方法检查病毒RNA。直接检测病毒抗原和定量检测病毒多靶点基因是今后的发展方向。     

新型冠状病毒上海株(nCoV-SH01)的分离和鉴定

新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)疫情对人类生命健康构成极大威胁。病毒的分离是构建新型冠状病毒(2019 novel coronavirus, 2019-nCoV)细胞感染模型和动物感染模型的基础。本研究利用冠状病毒易感的Vero E6细胞,从1例上海感染者的咽拭子中分离到一株2019-nCoV,命名为nCoV-SH01。对该毒株全基因组采用一代Sanger和二代Illumina法测序,发现该毒株与GenBank MN908947的同源性＞99.99%。免疫荧光检测显示,该毒株与COVID-19康复者的血清呈阳性反应。当nCoV-SH01感染Vero E6细胞后,导致典型的合胞体病变,细胞病变效应明显且进展迅速,提示nCoV-SH01可用于进一步建立2019-nCoV的细胞感染和动物感染模型,为开展致病性研究以及抗病毒药物和疫苗研发奠定了基础。     

SARS病毒与其他冠状病毒的基因组比较

本文利用生物信息学方法比较SARS病毒和其他冠状病毒基因组。通过数据库搜索,找出与SARS病毒基因组相似的核酸或蛋白质序列,并对相似序列进行比对,分析它们的共性和差异。结果表明,SARS病毒在基因组的组织上及结构蛋白质方面与现有冠状病毒有比较大的相似性,SARS病毒基因组与冠状病毒基因组相关。但是,SARS病毒基因组还存在一些特异性序列,ORF1a和S蛋白(特别是S1)的变化以及SARS—CoV特异性的非结构蛋白可能是SARS发病机理与传染特性区别于其他冠状病毒的分子基础。在全基因组水平上进行核酸单词出现频率分析,结果表明,SARS病毒远离已知的其他冠状病毒,单独成为一类。     

The Global Landscape of SARS-CoV-2 Genomes,Variants, and Haplotypes in 2019nCoVR

On January 22, 2020, China National Center for Bioinformation (CNCB) released the 2019 Novel Coronavirus Resource (2019nCoVR), an open-access information resource for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 2019nCoVR features a comprehensive integration of sequence and clinical information for all publicly available SARS-CoV-2 isolates, which are manually curated with value-added annotations and quality evaluated by an automated in-house pipeline. Of particular note, 2019nCoVR offers systematic analyses to generate a dynamic landscape of SARS-CoV-2 genomic variations at a global scale. It provides all identified variants and their detailed statistics for each virus isolate, and congregates the quality score, functional annotation, and population frequency for each variant. Spatiotemporal change for each variant can be visualized and historical viral haplotype network maps for the course of the outbreak are also generated based on all complete and high-quality genomes available. Moreover, 2019nCoVR provides a full collection of SARS-CoV-2 relevant literature on the coronavirus disease 2019 (COVID-19), including published papers from PubMed as well as preprints from services such as bioRxiv and medRxiv through Europe PMC. Furthermore, by linking with relevant databases in CNCB, 2019nCoVR offers data submission services for raw sequence reads and assembled genomes, and data sharing with NCBI. Collectively, SARS-CoV-2 is updated daily to collect the latest information on genome sequences, variants, haplotypes, and literature for a timely reflection, making 2019nCoVR a valuable resource for the global research community. 2019nCoVR is accessible at https://bigd.big.ac.cn/ncov/.     

Genome Warehouse: A Public Repository Housing Genome-scale Data

The Genome Warehouse (GWH) is a public repository housing genome assembly data for a wide range of species and delivering a series of web services for genome data submission, storage, release, and sharing. As one of the core resources in the National Genomics Data Center (NGDC), part of the China National Center for Bioinformation (CNCB; https://ngdc.cncb.ac.cn), GWH accepts both full and partial (chloroplast, mitochondrion, and plasmid) genome sequences with different assembly levels, as well as an update of existing genome assemblies. For each assembly, GWH collects detailed genome-related metadata of biological project, biological sample, and genome assembly, in addition to genome sequence and annotation. To archive high-quality genome sequences and annotations, GWH is equipped with a uniform and standardized procedure for quality control. Besides basic browse and search functionalities, all released genome sequences and annotations can be visualized with JBrowse. By May 21, 2021, GWH has received 19,124 direct submissions covering a diversity of 1108 species and has released 8772 of them. Collectively, GWH serves as an important resource for genome-scale data management and provides free and publicly accessible data to support research activities throughout the world. GWH is publicly accessible at https://ngdc.cncb.ac.cn/gwh.     

Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan,China

On 10 January 2020, a new coronavirus causing a pneumonia outbreak in Wuhan City in central China was denoted as 2019-nCoV by the World Health Organization (WHO). As of 24 January 2020, there were 887 confirmed cases of 2019-nCoV infection, including 26 deaths, reported in China and other countries. Therefore, combating this new virus and stopping the epidemic is a matter of urgency. Here, we focus on advances in research and development of fast diagnosis methods, as well as potential prophylactics and therapeutics to prevent or treat 2019-nCoV infection.     

Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection

The novel coronavirus 2019-nCoV has caused the pandemic of Wuhan pneumonia recently, posing a serious threat to global public health, and thus calling for the development of therapeutics and prophylactics. Here we showed that high titer anti-SARS-CoV spike protein serum cannot effectively neutralize 2019-nCoV infection. Based on our previous research, we developed SARS pseudovirus (SARS-PsV) and MERS pseudovirus (MERS-PsV) as immunogens to immunize mice. We found sera from mice treated with SARS-CoV S protein could potently cross-neutralize infection by SARS-CoV (50% neutralizing antibody titers, NT50 > 40, 000) and SARS-related coronavirus (NT50 > 7, 000), but weakly for 2019-nCoV infection NT50 < 100), implying that it may not be practical to treat 2019-nCoV infection with anti-SARS-CoV antibodies and that people with history of SARS-CoV infection many years ago may not be resistant to 2019-nCoV infection.     

新型冠状病毒的动物源性和传染源控制

根据现有的数据,新型冠状病毒(2019 novel coronavirus,2019-nCoV)比严重急性呼吸综合征冠状病毒(severe acute respiratory syndrome coronavirus,SARS-CoV)的传染性强、传播速度快、疫情规模大、病死率低。其传染性、传播速度和疫情规模似乎具有甲型流感病毒(influenza A virus)的特点。尽管2019-nCoV来源于何种动物尚无定论,但它与SARS-CoV同属冠状病毒,具有共同之处。如果流行过后 2019-nCoV没能在人群中持续传播和存在(如同SARS-CoV一样),则控制野生动物传染源乃重中之重;如果2019-nCoV获得了能在人群中持续传播的能力,预防控制策略将与SARS-CoV明显不同,疫苗便成为至关重要的手段。     

Old Weapon for New Enemy: Drug Repurposing for Treatment of Newly Emerging Viral Diseases

正Emerging and re-emerging viral diseases are a public health concern for the whole world and pose a major threat to human health and life. In last decades, numerous major outbreaks of emerging and re-emerging viral diseases with gross public concern were recorded in different regions,including Ebola in western Africa, Zika in South America,     

The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future

At the end of December 2019, a novel coronavirus, 2019-nCoV, caused an outbreak of pneumonia spreading from Wuhan, Hubei province, to the whole country of China, which has posed great threats to public health and attracted enormous attention around the world. To date, there are no clinically approved vaccines or antiviral drugs available for these human coronavirus infections. Intensive research on the novel emerging human infectious coronaviruses is urgently needed to elucidate their route of transmission and pathogenic mechanisms, and to identify potential drug targets, which would promote the development of effective preventive and therapeutic countermeasures. Herein, we describe the epidemic and etiological characteristics of 2019-nCoV, discuss its essential biological features, including tropism and receptor usage, summarize approaches for disease prevention and treatment, and speculate on the transmission route of 2019-nCoV.